Abstract:
Background: Isoniazid (INH) is one of the most potent anti-tuberculosis (TB) drugs and a key
component of the multi-drug regimen for the treatment of TB. Tuberculosis cases with initial INH
resistance are more at risk of poor clinical outcomes than those susceptible to INH among cases
receiving standard first-line chemotherapy. Drug resistance arises mainly from spontaneous
mutations in the Mycobacterium tuberculosis (M. tuberculosis) genome. Resistance to INH is more
complex mainly because it may involve mutations in one or more of several genes, such as katG,
inhA, ndh, kasA and ahpC. However, resistance in the katG and inhA genes is responsible for
approximately 65% of all instances of INH resistance. Continued usage of INH has been
compromised by the increasing prevalence of INH resistance among M. tuberculosis strains.
Furthermore, accurate molecular diagnosis of drug resistance depends on knowledge of
mechanisms conferring resistance to anti-TB drugs. Early detection of INH resistance is essential
to allow proper initial drug therapy and a decrease in MDR-TB.
Different M. tuberculosis lineages have been reported to be associated with different levels of
pathogenicity, are thought to drive resistance and to play a role in virulence characteristics and
transmission. Seven M. tuberculosis lineages have been identified, are geographically distributed
in diverse but specific regions and have been associated with specific resistance-conferring
mutations in the M. tuberculosis genome. The East Asian lineage (Beijing) has been shown to be
the foremost virulent and most dominant among the known lineages. It is the predominant lineage
in Far East Asia and causes more than 60% of TB cases in this region. The lineage has a worldwide
distribution and is also dominant in some parts of South Africa. The aim of this study was to
characterize INH resistance mutations in M. tuberculosis isolates from new and previously treated
patients and determine the association of mutations with TB lineages in the Tshwane region, South
Africa.
Methods: A total of 150 M. tuberculosis resistant isolates were obtained (2016 to 2019) from the
National Health Laboratory Service, Tshwane Academic Division. The study population included:
118/150 (79%) new cases and 32/150 (21%) previously treated cases. Of the new cases, 47/118
(40%) were females and 71/118 (60%) were males. Of the previously treated cases, 11/32 (34%)
were females and 21/32 (67%) were males. Genomic DNA was extracted using the GenoLyse®
kit (Hain Lifescience, Germany). Characterization of INH resistance-conferring mutations was
done using GenoType MTBDRplus (Hain Lifescience, Germany). Thereafter, screening of XDR-
TB was done using GenoType MTBDRsl (Hain Lifescience, Germany). Genotyping was
performed using spoligotyping, a PCR-based method. Association of M. tuberculosis lineages and
INH mutations was evaluated.
Results: Overall results showed that 117/150 (78%) were both RIF and INH resistant and 33/150
(22%) were RIF mono-resistant. Of the 33 pre-MDR-TB isolates, 12/33 (36%) were
phenotypically discrepant in RIF and INH resistance. Of these, 10/12 (83%) were new and 2/12
(17%) were previously treated TB cases. Mutation S315T of the katG gene was found in 75/118
(64%) of new TB cases and 13/32 (41%) in previously treated cases. The sensitivity and specificity
of LPA for detecting INH resistance was between 29% to 71% and 84% to 100% respectively.
Screening of MDR-TB isolates for XDR-TB showed that 139/150 were sensitive to second-line
injectable drugs (SLIDs) and 11/150 were resistant. Only 90/150 were susceptible to
fluoroquinolones (FLQs) and 60/150 were resistant. Spoligotyping identified 9 major distinct TB
families including East African Indian (EAI) (14%), Latin American and Mediterranean (LAM)
(13%), Beijing (27%), T-family (13%), S-family (7%), H-family (1%), X-family (7%), Manu2-
family (4%) and CAS-family (1%). Remaining isolates 13% of the isolates were orphans. Mutation
S315T of the katG gene in new TB cases was mostly associated with Beijing (18/118 or 15%) and
with T1-family (9/118 or 8%). In previously treated cases, mutation S315T was associated with
Beijing 5/32 (16%) and with X2 (3/32 or 9%). Furthermore, mutation C-15T in new TB cases was
mostly associated with Beijing (9/118 or 8%). However, the was no significant association
between INH resistance-conferring mutations and M. tuberculosis lineage in new and previously
treated cases.
Conclusion: This study showed that male gender is more prominently associated with resistance
to INH within the Tshwane region. This shows that male gender is prone to disease exposure than
females. The line probe assay MTBDRplus 2.0 is commonly used as a rapid diagnostic for drug
resistance to first-line drugs, including RIF and INH resistance. However, in comparison with
phenotypic methods, around 8% of isolates produced discrepant results, i.e. INH resistance missed
by the LPA. This indicates that a more discriminatory technique should be used to further analyse
INH susceptible isolates. A high genetic diversity of M. tuberculosis lineages was observed in both
new and previously treated cases. Furthermore, M. tuberculosis lineages associated with S315T
mutation within the Tshwane region appears to be spreading rapidly compared to previous studies
done in the region.